Optical Imaging wins FDA nod

The Retinal Function Imager is a non-invasive device to diagnose eye diseases.

Sources inform "Globes" that Optical Imaging Ltd. has received approval from the US Food & Drug Administration (FDA) for its non-invasive imaging device for the early diagnosis of eye disease.

The Rehovot-based company's Retinal Function Imager (RFI) is an integrated hardware and software turnkey system, providing a unique non-invasive, ophthalmic functional imaging system with novel capabilities for seeing problems in the eye. The RFI maps the retina to the resolution of single red blood cells moving through capillaries. The RFI offers clinicians and researchers insight into the pathogenesis of retinal diseases leading to better patient care.

Optical Imaging hopes to start marketing the RFI in the US, Europe and Japan in the near future, and has signed a marketing agreement with Topcon Medical, a leading US distributor of medical devices.

As part of the agreement Topcom is committed to selling at least 30 RFIs this year in the US. Optical imaging expects combined sales in the US, Europe and Japan of the RFI to reach NIS 15 million this year. The company's previous product to image the brain has sold NIS 14 million worth of units to date mainly to universities for research.

Published by Globes [online], Israel business news - www.globes-online.com - on February 8, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018